Capvizr
THE DEAL, AT A GLANCE

Healome Therapeutics

From the announcement
01
MoleculesDrug research
Medicine development
What it doesHealome Therapeutics is a UK ophthalmology company developing a platform eye-drop matrix technology aiming to improve retention, lubrication, protection, healing and…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Who is involvedBacked by Empirical Ventures, DEBRA Research, Cure EB, Oshen BioFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03What happenedHealome Therapeutics raised Seed, announced 2026-07-07From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
04Why it mattersHealome Therapeutics is using a seed round to advance a platform eye-drop matrix technology for ocular surface diseases.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Healome Therapeutics · Financing Record

Explore source-linked visual explanations for Healome Therapeutics. Unsupported claims are withheld while source review continues.

Record 7639 · Recorded date: 2026-07-07

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime